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FOOTNOTES TO THE TEXT 
 
1The abbreviations used are: AA, arachidonic acid;  PLA2, phospholipase A2; 
cPLA2α, cytosolic phospholipase A2α; iPLA2, Ca2+-independent phospholipase A2; 
BEL, bromoenol lactone; MAFP,  methyl arachidonyl fluorophosphonate; Con A, 
concanavalin A; PC, choline glycerophospholipids; PE, ethanolamine 
glycerophospholipids. 
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ABSTRACT 
 
Previous studies have demonstrated that U937 cells are able to mobilize 
arachidonic acid (AA) and synthesize prostaglandins in response to receptor-
directed and soluble stimuli by a mechanism that involves the activation of Group 
IV cytosolic phospholipase A2α (cPLA2α). In this paper we show that these cells 
also mobilize AA in response to an oxidative stress induced by H2O2 through a 
mechanism that appears not to be mediated by cPLA2α but by the calcium-
independent Group VI phospholipase A2 (iPLA2). This is supported by the following 
lines of evidence: (i) the response is essentially calcium-independent, (ii) is 
inhibited by bromoenol lactone, and (iii) is inhibited by an iPLA2 antisense 
oligonucleotide. Enzyme assays conducted under a variety of conditions reveal 
that the specific activity of the iPLA2 does not change as a result of H2O2 exposure, 
which argues against the activation of a specific signalling cascade ending in the 
iPLA2. Rather, the oxidant acts to perturb membrane homeostasis in a way that the 
enzyme susceptibility/accesibility to its substrate increases, and this results in 
altered fatty acid release. In support of this view, not only AA, but also other fatty 
acids were found to be liberated in an iPLA2-dependent manner in the H2O2-treated 
cells. Collectively, these studies underscore the importance of the iPLA2 in 
modulating homeostatic fatty acid deacylation reactions, and documents a 
potentially important route under pathophysiological conditions for increasing free 
fatty acid levels during oxidative stress. 
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Phospholipase A2 (PLA2)1 constitutes a key regulatory step in the production of 
prostaglandins because it catalyzes the release of arachidonic acid (AA) from the 
sn-2 position of phospholipids, making the free fatty acid accessible to 
prostaglandin synthases. At present, fourteen different PLA2 groups have been 
identified [1, 2]. These include ten groups of enzymes utilizing a catalytic histidine, 
which show millimolar requirements for Ca2+ and are collectively referred to as the 
secreted PLA2s (Groups I, II, III, V, IX, X, XI, XII, XIII, XIV) [1, 2], and two groups of 
intracellular, high molecular mass enzymes, which utilize a catalytic serine (Groups 
IV and VI). Group IVA PLA2, also known as cytosolic PLA2α  (cPLA2α) is a highly 
regulated, Ca2+-dependent enzyme [1, 2]; whereas, Group VI PLA2, or iPLA2, is 
Ca2+-independent [1, 2]. 
 Among these PLA2s, Groups IIA, V, and IVA have repeatedly been shown to 
be responsible for AA release and prostaglandin generation in different systems [3-
5]. In phagocytic cells, Group VI PLA2 has been primarily implicated in basal fatty 
acid reacylation reactions by controlling the cellular level of 
lysophosphatidylcholine acceptors [6]. In other cell types, notably heart and 
pancreatic islets, the enzyme has also been implicated in receptor-mediated AA 
release, based on the effects of a bromoenol lactone suicide inhitor (BEL) [6].  
Recent work has shown that reactive oxygen intermediates enhance AA 
release and prostaglandin production in different cell systems, but the molecular 
mechanism responsible for these effects has not been clarified. Activation of an 
intracellular PLA2 has been pointed out as the most likely mechanism for AA 
mobilization in vascular smooth muscle cells, stromal cells, and striatal neurons 
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exposed to H2O2 [7-11]. In other systems however, diminished AA incorporation 
into phospholipids, not PLA2 activation, has been suggested to be the event 
responsible for free AA accumulation [12, 13]. In an attempt to reconcile these 
conflicting results, we sought to investigate the ability of H2O2 to induce AA 
mobilization from human monocytic U937, cells and the molecular mechanism 
involved in this process. U937 cells contain both cPLA2α and iPLA2 and have been 
shown to release AA and produce prostaglandins in response to a variety of 
receptor-mediated and soluble agonists in a cPLA2α-regulated manner [14, 15]. 
Utilizing a variety of approaches, we show here that H2O2-induces AA mobilization 
in U937 cells by a Ca2+-independent mechanism that involves not cPLA2α, but 
rather the iPLA2. Importantly however, the results indicate that the iPLA2-mediated 
AA release does not reflect a true activation of the enyme (i.e. a stable increase in 
the enzyme’s specific activity) but rather an increased accessibility of the iPLA2 
towards its substrate. These results underscore the key role of iPLA2 in modulating 
basal fatty acid deacylation reactions. 
 
 
EXPERIMENTAL PROCEDURES 
 
Materials – [5,6,8,9,11,12,14,15-3H]AA (100 Ci/mmol) was from Amersham. 
Bromoenol lactone, (E)-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-
pyran-2-one (BEL) and methyl arachidonyl fluorophosphonate (MAFP) were from 
Cayman (Ann Arbor, MI). The specific cPLA2α inhibitor pyrrophenone was 
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generously provided by Dr. K. Seno (Shionogi Co., Osaka, Japan) [16-18]. All other 
reagents were from Sigma.  
Cell culture – U937 cells were maintained in RPMI 1640 medium 
supplemented with 10% (v/v) fetal calf serum, 2 mM glutamine, penicillin (100 
units/ml) and gentamycin (24 µg/ml). The cells were incubated at 37°C in a 
humidified atmosphere of CO2/O2 (1:19) at a cell density of 0.5-1 x 106 cells/ml in 
12-well plastic culture dishes (Costar). Cell differentiation was induced by treating 
the cells with 35 ng/ml PMA for 24 h [19, 20]. 
AA release experiments – The cells were labeled with 0.5 µCi/ml [3H]AA for 
18 h. After this period, the cells were washed and placed in serum-free medium for 
1 h before the addition of the appropriate stimulus in the presence of 0.5 mg/ml 
bovine serum albumin. The supernatants were removed, cleared of cells by 
centrifugation, and assayed for radioactivity by liquid scintillation counting. 
For analysis of [3H]AA metabolites released into the supernatant, the 
stimulations were conducted in the absence of albumin. The supernatant was 
acidified to pH 3.5 with 5 M formic acid, and extracted twice with 3 ml of ethyl acetate. 
The ethyl acetate was dried under a stream of nitrogen, the residue dissolved in a 
few drops of chloroform/methanol (2:1, v/v) and chromatographed on Silicagel G-60 
plates. Unlabeled prostaglandin standards were used as carriers. The solvent system 
used was chloroform/methanol/acetic acid/water (90:8:1:0.8, by vol.) [21].  
Treatment of the cells with antisense oligonucleotides – The antisense 
oligonucleotides utilized in these studies were derived from prior publications 
reporting their effects [22-24]. The iPLA2 antisense sequence corresponded to 
nucleotides 59-78 in the murine group VI iPLA2 sequence, that is conserved in 
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human group VI iPLA2 [25, 26]. The antisense or sense oligonucleotides were 
mixed with lipofectamine, and complexes were allowed to form at room 
temperature for 10-15 min. The complexes were then added to the cells, and the 
incubations were allowed to proceed under standard cell culture conditions. The 
final concentrations of oligonucleotide and lipofectamine were 1 µM and 10 µg/ml, 
respectively. Oligonucleotide treatment and culture conditions were not toxic for the 
cells as assessed by the Trypan blue dye exclussion assay and by quantitating 
adherent cell protein. 
 iPLA2 assay – Briefly, U937 cell aliquots were incubated for 30 min at 37°C 
in 100 mM Hepes (pH 7.5) containing 5 mM EDTA and 100 µM phospholipid 
substrate (pH 7.5), in a final volume of 250 µl. The substrates utilized in the assay 
were [3H]AA-labeled PC and [3H]AA-labeled PE, and they were used in the form of 
sonicated vesicles in buffer [15]. In some experiments, the EDTA was replaced by 
1 mM CaCl2. iPLA2 activity was also measured utilizing the mixed-micelle assay 
described by Dennis and colleagues [27], and the mammalian membrane substrate 
assay described by Diez et al. [28].  
 Preparation of substrates for the iPLA2 assay – [3H]AA-labeled PC and PE 
were isolated from cellular lipids of U937 cells incubated for 24 h with the 
exogenous 3H-labeled fatty acid (0.5 µCi/ml). Labeled phospholipids were purified 
by thin-layer chromatography and tested for purity as described previously [15]. 
Labeled U937 cell membranes were prepared by adding 0.5 µCi/ml [3H]AA to the 
U937 cell cultures for 18 h. Total cellular membranes were prepared by sucrose 
centrifugation exactly as described by Diez et al. [28]. 
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 Lipid peroxide determination – The amount of lipid peroxides in membranes 
was quantified by the thiobarbituric acid-reactive substance assay [29]. The 
samples were mixed with 1 ml 0.67% thiobarbituric acid and 0.5 ml 20% 
tricholoroacetic acid, and the mixtures were incubated in a boling water bath for 20 
min. After cooling the tubes on ice, the reaction mixture was centrifuged at 3000 x 
g for 10 min and absorbance of the supernatant was read at 532 nm. The 
concentration of thiobarbituric acid-reactive substances, which is directly 
proportional to the amount of lipid peroxides in the samples, was calculated using 
tetraethoxy propane as a reference standard. 
Data presentation – Assays were carried out in duplicate or triplicate. Each 
set of experiments was repeated at least three times with similar results. Unless 
otherwise indicated, the data presented are from representative experiments. 
 
 
RESULTS 
 
AA mobilization in H2O2-treated U937 cells -  We began the current study by 
determining whether H2O2 was capable of causing the extracellular release of AA 
from U937 cells. To this end, the cells, labeled with 0.5 µCi [3H]AA, were exposed 
to different concentrations of H2O2 for various periods of time. As shown in Fig. 1, 
H2O2 did induce a concentration- and time-dependent release of [3H]AA from the 
cells (Fig. 1). Maximal effects of H2O2 on AA release were observed at a 
concentration of 500 µM (Fig. 1A). Such a concentration was therefore used in all 
subsequent experiments. Fig. 1B shows that, after a lag of about 5-15 min, H2O2-
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induced AA release proceeded linearly for the following hour, proceeding at a  
slower rate thereafter. That the kinetics of AA release in response to H2O2 does not 
show saturation within 1 h of treatment is in stark contrast with the kinetics of AA 
release in response to the receptor-directed agonist Con A [20], which is also 
shown in Fig 1B for comparison.  
The composition of the 3H-released material was analyzed by thin-layer 
chromatography and the results are shown in Table I. Treatment of the cells with 
H2O2 significantly increased prostaglandin production, most notably of prostaglandin 
E2 and D2, but unmetabolized free AA was the most abundant labeled compound 
released into the medium.  
PLA2 Inhibition Studies – To address the involvement of the different PLA2 
forms in H2O2-induced AA release, we first utilized MAFP, a dual cPLA2/iPLA2 
inhibitor [30]. As shown in Fig. 2A, MAFP significantly blocked the response to 
H2O2. To distinguish whether the inhibition of MAFP on AA release was due to 
either cPLA2α or iPLA2, we conducted studies with BEL, a compound that 
manifests a marked selectivity for inhibition of iPLA2 versus cPLA2α in vitro [6]. Fig. 
2A also shows that BEL, at concentrations that are known to block cellular iPLA2, 
exerted a significant inhibitory effect on the H2O2-induced AA mobilization. As a 
control for these experiments, the effects of these inhibitors on Con A-induced AA 
mobilization was also studied (Fig. 2B). MAFP, but not BEL, inhibited the response, 
thus suggesting the involvement of cPLA2α but not of iPLA2 under these 
conditions. 
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Fig. 3 shows the effect of pyrrophenone, a compound that exhibits more 
than 1000-fold selectivity for inhibition of cPLA2α versus iPLA2 [18, 31].  Whereas 
pyrrophenone exerted no significant effect on the H2O2-induced AA release, it 
completely inhibited the response to Con A (IC50 ~0.2 µM). Collectively, these 
results suggest that cPLA2α mediates the Con A-induced release of AA but has no 
effect on the H2O2 response. The latter appears to involve the iPLA2. 
To further define the role of iPLA2 in U937 cell release, we also examined 
the effects of an antisense oligonucleotide to iPLA2. The iPLA2 antisense 
oligonucleotide used was the human counterpart of the murine one that we and 
others have succesfully employed elsewhere [21-23]. Using this antisense, a ~70% 
decrease of both the immunoreactive iPLA2 protein (Fig. 4A) and of cellular iPLA2 
activity (Fig. 4B) was achieved, in agreement with previous estimates [21, 22]. The 
antisense to iPLA2 had no effect on the expression of cPLA2α (Fig. 4A). Under 
these conditions, a significant decrease in the AA release response of H2O2-treated 
cells was observed (Fig. 4C), which provides additional evidence for the 
involvement of the iPLA2 in this process. Control antisense experiments utilizing 
Con A as a trigger for AA release revealed the expected lack of effect of the iPLA2 
antisense (Fig. 4C). 
Characterization of the H2O2 effect on iPLA2 – Collectively, the above data 
suggest the involvement of iPLA2 in the AA mobilization response induced by H2O2 
in U937 cells. Since iPLA2 is a Ca2+-independent enzyme, one might expect the 
H2O2-induced AA mobilization process to be Ca2+-independent as well. To evaluate 
this possibility, the following approaches were undertaken. In the first place, the 
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cells were exposed to H2O2 in the absence of Ca2+ in the incubation medium and 
the effect on AA mobilization was studied. Fig. 5 shows that this strategy did not 
modify the H2O2 response. As a control, the effect of Ca2+ deprivation on the Con A 
response was also studied and the response was strongly blunted (Fig. 5). In the 
next series of experiments, the cells were depleted of their intracellular Ca2+ by 
treating them with 40 µM quin2/AM plus 1 mM EGTA in a Ca2+-free medium. This 
procedure buffers and clamps the intracellular calcium concentration at very low 
levels (about 10-8 M) [32]. Under these conditions, the AA response to H2O2 
remained unchanged, whereas the Con A response was abolished (Fig. 5). 
Collectively, these results indicate that AA mobilization in response to H2O2 does 
not require Ca2+, which is consistent with the participation of an iPLA2. 
Unlike cPLA2α, iPLA2 does not show any apparent substrate specificity [6]. 
Thus, if iPLA2 is involved in fatty acid release in the H2O2-treated cells, one might 
expect to observe not only the release of AA but also of other fatty acids. To 
address this possibility, experiments were conducted where the cells were labeled 
with [3H]oleic acid prior to exposure to H2O2. H2O2 induced a low but measurable 
release of oleic acid. When the cells were exposed to Con A instead, release of 
oleic acid was not observed (Fig. 6). Altogether, the results are consistent with the 
the finding that Con A signals through the AA-specific cPLA2α but not through the 
iPLA2. H2O2, in contrast, appears to catalyze fatty acid mobilization through the 
fatty acid-nonspecific iPLA2. 
Studies on the Regulation of iPLA2 Activity -  If the H2O2 effect on the iPLA2 
is truly an ‘activating’ one, an increase in the specific activity of the enzyme is to be 
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expected. Homogenates of U937 cells, either untreated or treated with H2O2, were 
prepared and assays were conducted to assess iPLA2 activity utilizing a vesicle 
substrate assay. Under these conditions we failed to detect any change in the 
iPLA2 specific activity of homogenates from H2O2-treated cells versus untreated 
cells. Conversely, definite increases in the Ca2+-dependent activity of the 
homogenates could be detected if the cells were previously treated with Con A 
(Fig. 7). These changes, which most likely correspond to increases in cPLA2 
activity [14, 15], suggest that our inability to detect changes in the iPLA2 specific 
activity may not be due to technical issues. Experiments in which iPLA2 activity 
was measured utilizing the mixed micelle assay described by Dennis and 
colleagues [27] also failed to reveal any change in the iPLA2 activity of the 
homogenates (not shown). 
As a third approach, we utilized the mammalian membrane assay system 
described by Diez and colleagues [28]. In this system, purified [3H]AA-labeled 
mammalian membranes are used as a substrate. Utilizing this assay, again no 
differences in the iPLA2 activity of untreated cells vs. H2O2-treated cells could be 
demonstrated. Importantly however, when iPLA2 activity of homogenates from 
either untreated cells or H2O2-treated cells was assayed towards H2O2-treated 
membranes, a low but significant increase in the iPLA2 activity could be measured 
(Fig. 8). Thus, it must be the physical state of the substrate and not the intrinsic 
activity of the enzyme what changes after H2O2 exposure. Moreover, the 
membranes from H2O2-treated cells showed significantly elevated levels of lipid 
peroxides, as quantified by measuring thiobarbituric acid-reactive substances (73 ± 
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12 pmol/mg protein in H2O2-treated membranes vs 31 ± 9 pmol/mg protein in 
membranes from untreated cells, mean ± S.E.M., n=4). 
 
 
DISCUSSION 
 
 Phagocytic cells produce reactive oxygen intermediates such as superoxide 
anion and hydrogen peroxide in response to a variety of agonists [33]. While the 
production of these oxygen metabolites plays an important role in cellular signaling 
and host defense, their uncontrolled production constitutes a serious 
pathophysiological factor for a wide variety of vascular-based disorders [33]. 
Oxidative damage is often associated with AA mobilization from cells from the 
vascular system, such as endothelial cells, smooth muscle cells, platelets and 
phagocytes. Thus, interactions between reactive oxygen intermediates and AA 
metabolites are of particular importance.  
In this study, H2O2 was used to investigate mechanisms of AA mobilization 
in phagocytic cells under an oxidative stress, and the data suggest that oxidant-
induced fatty acid mobilization from U937 phagocytes does not depend on cPLA2α 
but rather on a iPLA2-like activity. This is based on several lines of evidence, such 
as the use of chemical inhibitors and of antisense oligonucleotide techniques. 
Examination of the time-course of AA mobilization in response to H2O2  revealed 
that, after a short lag, the response proceeded linearly with time, showing signs of 
saturation only after 2 h exposure to the oxidant. Such a kinetics strongly contrasts 
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with the response of the cells to Con A, a well-known receptor agonist of U937 
cells, which shows the typical saturation kinetics that is expected from a highly 
regulated cellular response such as AA release. In keeping with the above, when 
assayed in a cell-free system, cellular iPLA2 activity did not change. Of note, 
assays were conducted under three different experimental conditions, namely a 
vesicle assay, a mixed micelle assay and a natural membrane assay. Since the 
results were the same regardless of the assay system utilized, it appears likely that 
the intrinsic activity of the iPLA2 does not change after exposure of the cells to 
H2O2. This conclusion argues against the possibility of a stable activation of the 
iPLA2 as the mechanism for H2O2-mediated AA release in U937 cells.  
 Interestingly, when membranes from H2O2-treated cells were used in the 
assay, the iPLA2 activity measured was found to be significantly higher than that 
found in membranes from otherwise unstimulated cells. Therefore, treating the 
cells with H2O2 results in facilitated iPLA2 attack on membrane phospholipids. We 
have found that membranes from H2O2-treated cells contain significantly higher 
amounts of lipid peroxides than membranes from untreated cells. Thus the data 
suggest that lipid hydrolysis by iPLA2 occurs more readily in H2O2-treated cells 
because of changes in the physical state of membrane substrates, which may 
result, at least in part, from lipid peroxide accumulation. How this facilitated 
catalysis occurs is presently unknown, but a number of factors that alter membrane 
lipid packing are well documented to increase fatty acid release both in vitro and in 
vivo [34, and references therein].  
Taken together, these results suggest a model for fatty acid mobilization in 
H2O2-treated cells whereby the oxidant induces lipid oxidation which results in 
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accumulation of lipid peroxides at the membrane. These lipid peroxides destabilize 
the membrane and render it susceptible to attack by the iPLA2, which then starts 
releasing increased amounts of fatty acids. An important aspect of the above 
model is that this fatty acid release occurs in the absence of cPLA2α activation, 
which underscores the apparent lack of a ‘regulated signaling’ component in the 
process. Still, a mechanism such as the one proposed here may  be of importance 
under certain pathophysiological settings (i.e. oxidative stress), where increased 
iPLA2 activity may account for a significant phospholipid hydrolysis before cellular 
homeostasis is re-established. In turn, these results highlight the key role of iPLA2 
in modulating basal fatty acid deacylation reactions.  
Whether iPLA2 is also involved in regulated phospholipid hydrolysis in 
phagocytic cells is unknown at present. However, the fact that multiple splice 
variants of iPLA2 exist in some cells and that other iPLA2s distinct from the 
‘classical’ group VI enzyme have recently been described [6], suggest the 
possibility that iPLA2 may be subject to complex regulatory mechanisms that differ 
among cell types. Two recent reports utilizing cells overexpressing group VI iPLA2 
have been shown the enzyme to be responsive to Ca2+ ionophore in HEK293 cells 
[35] and to glucose plus cAMP-elevating agents in INS-1 insulinoma cells [36], thus 
suggesting that the enzyme is capable of playing some signaling roles in cells. 
Whether in addition to its housekeeping role in U937 cells and phagocytic cells in 
general, the group VI iPLA2 also plays a signaling role is currently under study. 
 Analysis of the AA metabolites produced after exposure to the cells to H2O2 
revealed a significant production of prostaglandins, particularly the pro-
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inflammatory prostaglandins E2 and D2. This suggests that an immediate biological 
consequence of H2O2-induced AA release is to generate mediators that propagate 
and/or amplify the oxidative injury. Interestingly, a major portion of the material 
released after H2O2 exposure remained as free unmetabolized AA, which raises 
the possibilty that its metabolism to eicosanoid mediators might not be its only 
biological fate. H2O2 is known to induce apoptosis in a number of cells including 
phagocytes [37, 38] and there is evidence that unesterified AA within cells can 
signal apoptosis [39, 40]. Moreover, treating U937 cells with BEL has been show to 
retard Fas- and tumor necrosis α/cycloheximide-mediated apoptosis [41, 42]. 
Taking all these findings together, it is tempting to speculate that the AA liberated 
by iPLA2 in H2O2-treated cells may play a role in oxidant-induced apoptosis in 
these cells. Studies are currently in progress to investigate this attractive 
possibility. 
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FIGURE CAPTIONS 
 
Figure 1.  H2O2-induced [3H]AA release from U937 cells. A, dose-response of the 
H2O2 effect (60-min incubation). B, time-course of [3H]AA release in response to 
500 µM H2O2 (closed circles), 100 µg/ml Con A (open circles), and in the absence 
of stimulation (open triangles). 
 
Figure 2. Effect of MAFP and BEL on [3H]AA release from U937 cells. The cells 
were treated with the indicated concentrations of MAFP (open circles) or BEL 
(closed circles) for 30 min before the addition of 500 µM H2O2 (A) or 100 µg/ml Con 
A (B), and the incubations proceeded for 60 min. Results are given as a 
percentage of the response obtained in the absence of inhibitors. 
 
Figure 3. Effect of pyrrrophenone on [3H]AA release from U937 cells. The cells 
were treated with the indicated amounts of pyrrophenone for 30 min before the 
addition of 500 µM H2O2 (closed symbols) or 100 µg/ml Con A (open symbols) and 
the incubations proceeded for 60 min. Results are given as a percentage of the 
response obtained in the absence of inhibitors. 
 
Figure 4. iPLA2 antisense oligonucleotide inhibits iPLA2 protein expression and 
activity, and AA release in H2O2-treated U937 cells.  The cells were either 
untreated (control) or treated with sense or antisense oligonucleotides. A, Total 
cytoplasmic protein was evaluated by immunoblot for iPLA2 (top) or cPLA2α 
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(bottom). B, effect on cellular iPLA2 activity. C,  effect on the AA mobilization 
response triggered by 500 µM H2O2 (closed bars), 100 µg/ml Con A (open bars), or 
neither (gray bars). 
 
Figure 5. Effect of Ca2+ on [3H]AA release from U937 cells.  The cells were treated 
with 500 µM H2O2, 100 µg/ml Con A or neither (control) as indicated for 60 min in 
medium with 1.3 mM CaCl2 (open bars), Ca2+-free medium with 1 mM EGTA 
(closed bars), or Ca2+-free medium with 1 mM EGTA plus 40 mM quin2/AM. 
Afterward, supernatants were assayed for [3H]AA release. 
 
Figure 6. Oleic acid release from U937 cells. The cells, labeled with [3H]oleic acid, 
were treated with 500 µM H2O2, 100 µg/ml Con A or neither (control) as indicated, 
for 60 min. Afterward, supernatants were assayed for [3H]oleic acid release. 
 
Figure 7. PLA2 activity of homogenates from U937 cells. Homogenates from 
untreated cells (control) or from cells treated with either 500 µM H2O2 or 100 µg/ml 
Con A were prepared, and PLA2 activity was measured in the absence (open bars) 
or presence (closed bars) of 1 mM CaCl2 in the assay mix.  
 
Figure 8. Time-course of PLA2 activity using a natural membrane as substrate. 
Untreated (open circles) and H2O2-treated (closed circles), [3H]AA-labeled 
membranes were incubated with U937 cell homogenates (as a source of enzyme). 
Reactions were stopped at different time points and free [3H]AA was isolated by 
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thin-layer chromatography. PLA2 activity was expressed as the percentage of 
hydrolysis of the labeled membrane substrate.  
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TABLE I 
 
Prostaglandin production by U937cells exposed to H2O2. 
 
Eicosanoid Control H2O2 
   
PGE2 2.7 ± 0.4 7.1 ± 0.2 
PGD2 1.9 ± 0.3 6.7 ± 0.2 
6-keto-PGF2α 0.9 ± 0.1 1.9 ± 0.1 
TXB2 0.5 ± 0.1 1.5 ± 0.1 
AA 8.7 ± 0.4 20.7 ± 0.4 
 
       
U937 cells, prelabeled with [3H]AA, were untreated ot treated with 500 µM H2O2 for 
60 min. Supernatants were taken off and the different metabolites were separated by 
thin-layer chromatography as described in Materials and Methods. The data are 
expressed in dpm x 10-3. PGE2, prostaglandin E2, PGD2, prostaglandin D2, 6-keto-
PGF1α, 6-ketoprostaglandin F1α, TXB2, thromboxane B2.  
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